Simplify Logo
Sanofi

Sanofi

Global pharma company; vaccines and R&D

Associate Director Incentive Compensation

Full-TimeDeadline 10/30/26
$133.5k - $192.8k/yr
Senior
Bachelor's, MBA
Cambridge, MA, USA+1 more

More locations: Morristown, NJ, USA

In Person

About the job

Requirements
  • At least 5 years of experience in similar roles in biotechnology or pharmaceuticals.
  • An undergraduate degree is required.
  • Emotional intelligence, change management, communication, and financial acumen are required.
  • Ability to drive change as a forward thinker within an organization, cultivate support, and maximize contributions from cross-functional team members.
  • Knowledge of modern go-to-market models, customer engagement processes, and key performance indicators, including Account versus healthcare professional selling models, key account management and group purchasing organization strategies, hybrid selling, and representative and home-office orchestration.
  • Knowledge of modern incentive compensation plans across therapeutic areas, including lead and lag indicators and execution-adherence integration.
  • Knowledge of industry-standard data sets, including IQVIA Xponent, IQVIA DDD, 867, and de-identified specialty pharmacy and hub data.
  • Knowledge of systems including Veeva, Salesforce, Snowflake, and Power BI.
  • Ability to lead without authority in a matrix environment.
  • Presentation skills and the ability to tell a story supported by facts.
  • Project and program management capabilities.
Responsibilities
  • Lead the strategy, design, deployment, and execution of brand sales architecture, incentive compensation plans, contests, and execution adherence.
  • Align and accelerate key therapeutic-area business drivers set by the business.
  • Lead management of field-force architecture, incentive design, optimization and deployment, and measurement of field execution and systems adherence using modern industry go-to-market and customer-engagement models.
  • Maintain the run state of these activities through normal weekly, monthly, and quarterly processes.
  • Coordinate and support Sales Operations activities, including Quarterly Business Activities, Veeva enhancements, data and reporting enhancements, and field triggers.
  • Create opportunities for brand-performance efficiencies through process improvements, vendor leverage, and data analysis; partner with brands to implement solutions and track return on investment.
  • Recommend changes and make suggestions to BOS and Business Unit teams using insights and operational expertise to drive increased performance.
  • Collaborate with colleagues in similar roles across business units to share best practices, drive consistency and efficiencies, and effectively leverage support teams.
Desired Qualifications
  • An MBA is preferred.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Belén Garijo upgraded 2026 guidance on July 30 after strong Dupixent and new approvals.
  • Paulo Fontoura starts September 1, 2026, sharpening R&D execution under a pipeline reset.
  • Tzield, Wayrilz, Cenrifki, and Sarclisa approvals broaden growth beyond Dupixent in 2026.

What critics are saying

  • Dupixent drove Q2 2026 sales, exposing Sanofi to patent expiry after 2030.
  • Sanofi killed amlitelimab and itepekimab in 2026, signaling a fragile late-stage pipeline.
  • Texas sued Sanofi on February 19, 2026; adverse judgments could multiply commercialization costs.

What makes Sanofi unique

  • Dupixent and vaccines give Sanofi global scale across immunology, respiratory, and prevention.
  • Sarclisa Escena won FDA approval July 10, 2026 as first on-body injector cancer therapy.
  • Frankfurt insulin manufacturing secures European supply, backed by €400 million German aid September 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Electra Therapeutics
Sep 11th, 2026
Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders and Cancer

SOUTH SAN FRANCISCO, CA, October 22, 2025 – Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today announced an oversubscribed $183 million Series C financing. The round was co-led by Nextech and EQT Life Sciences...

La Croix
Sep 8th, 2026
EU approves $448M German subsidy to Sanofi for insulin production security

The European Commission has approved a €400 million subsidy from Germany to pharmaceutical company Sanofi to maintain its Frankfurt insulin production site. The Commission stated that without this aid, Sanofi would close the German facility, reducing insulin supply security across the European Economic Area. The subsidy aims to compensate Sanofi for costs related to a service of general economic interest, strengthening insulin supply resilience for German patients. In return, Sanofi must build a new insulin factory in Frankfurt by 31 December 2032 and guarantee minimum annual production of 1.1 tonnes until 2042. Sanofi is among the world's leading insulin producers. The company announced in 2024 a €1.3 billion investment in Frankfurt to construct a new complex replacing existing facilities.

StreetInsider
Aug 25th, 2026
Altesa BioSciences wins award for oversubscribed $75M Series B to advance COPD therapies

Atlanta-based Altesa BioSciences has won the 2026 Georgia Life Sciences Golden Helix Award for Deal of the Year, recognising its oversubscribed $75 million Series B financing round. The funding, led by Forbion with participation from Sanofi, Medicxi, Pitango, and Atlantic Partners, will advance the clinical-stage pharmaceutical company's lead therapy, vapendavir. Vapendavir is an investigational oral treatment for chronic lung diseases including COPD and asthma. The drug is currently being evaluated in the Phase 2b CARDINAL trial, which will enrol 900 COPD patients across the US and UK. The Georgia Research Alliance Venture Fund was an early investor in Altesa. The company's scientific founders previously helped develop molnupiravir, one of the earliest COVID-19 treatments.

Business Wire
Aug 13th, 2026
Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Epicrispr Biotechnologies Closes $90 Million Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Morningstar
Aug 12th, 2026
InduPro raises $77M Series B, doses first patient in Phase 1 trial of bispecific ADC for lung cancer

InduPro has closed a $77 million Series B financing round and dosed its first patient in a Phase 1 study of IDP-001, its lead oncology programme. The biotechnology company is developing IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen, for treating advanced squamous non-small cell lung cancer and other solid tumours. The Column Group led the financing round, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Proceeds will support Phase 1 clinical development and early proof-of-concept data generation for IDP-001, whilst advancing InduPro's broader preclinical pipeline. InduPro uses a proximity-guided platform to map protein spatial relationships on cell surfaces for discovering selective co-target pairs.